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Ocular tuberculosis (TB) is a challenging clinical entity, pre-
senting hurdles in diagnosis and management for both
ophthalmologists and infectious disease specialists. Early
diagnosis and prompt treatment may be sight-saving in
patients with ocular TB. However, diagnostic obstacles pre-
sent the greatest limitations in understanding and treating
ocular TB in 2008.
Ocular TB epidemiology
At the population level, ocular TB is not common, but never-
theless is dealt with regularly in referral centers. The inci-
dence depends on the population studied. Donahue reviewed
the ophthalmic records of over 10 000 patients with primarily
pulmonary TB who were evaluated in the eye clinic of the
Mattapan Sanatorium, in Boston, Massachusetts, USA.1 He
found 1.4% with ocular TB. However, a 1997 study from Spain2* Corresponding author. 501 Smyth Rd, K1H 8L6, Canada.
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selected patients with culture-proven systemic TB seen in a
university hospital had ocular TB. Of these 100 patients, 45%
were co-infected with HIV. As a fraction of uveitis cases, the
prevalence of ocular TB also varies by area. In isolated
descriptive studies, it has been estimated to be under 1%
in the USA,3 4% in China,4 6% in Italy,5 7% in Japan,6 and 16% in
Saudi Arabia.7
Clinical presentation
Extraocular TB
TB may affect the eye by direct invasion of the tubercle
bacillus following hematogenous dissemination with local
destruction and inflammation, or via a hypersensitivity reac-
tion to the bacillus located elsewhere in the body. Ocular TB
has several potential manifestations.8 It can appear on the
external eye as a lid abscess or manifest as chronic blephar-
itis or atypical chalazions. It can present as a mucopurulent
conjunctivitis with regional lymphadenopathy. It can also
present as a phlyctenule (an inflammatory nodule at the
junction of the cornea and sclera), infectious keratitis,Published by Elsevier Ltd. All rights reserved.
Ocular tuberculosis 433inflammation within the cornea stroma (interstitial kerati-
tis), or as an infectious scleritis. All of these presentations are
rare and are easy to diagnose as material can be obtained for
culture and biopsy. Rarely, orbital disease can also occur.
Intraocular TB
The greater challenge is the more common but difficult to
diagnose TB uveitis. Uveitis from TB is intraocular and often
involves delicate structures that are difficult or impossible to
biopsy or culture. It may present as an iritis or iridocyclitis
(iris and ciliary body involved). The iritis may be granuloma-
tous. Granulomatous iritis presents as an aggressive anterior
uveitis with smudgy inflammatory exudates on the cornea
endothelium (granulomatous keratic precipitates) or the
aggressive iritis may be accompanied by granulomatous
nodules of the iris (Koeppe or Busacca nodules). The intrao-
cular inflammation may involve the eye in the area behind
the lens and just above the meeting of the end of the retina
with the ciliary body (intermediate uveitis). Intermediate
uveitis from TB tends to be particularly non-specific in terms
of its clinical presentation. Intermediate uveitis is distin-
guished from iritis by the presence of cells in the anterior and
mid-vitreous with sometimes ‘snowball’ opacities and depos-
its over the inferior junction of the retina and ciliary body.
More commonly, intraocular TB presents with involvement of
the posterior part of the eye. A vitritis, a retinitis and/or
choroiditis, and a retinal vasculitis will be the presenting
clinical scenario. Choroidal or retinal granulomas may be
present to help with the diagnosis, but they may be absent as
well. Choroidal lesions including granulomas are probably the
most common findings in confirmed cases of ocular TB.2,8 If
choroidal lesions are detected they can be an early sign of
disseminated disease. The optic nerve may be inflamed
mimicking an ischemic optic neuropathy. It can also present
as an optic neuritis or papillitis. If the inflammation is
extensive and involves these posterior structures, an endo-
genous endophthalmitis results when the infection and
inflammation extends through the choroids and retina to
involve the vitreous, which mimics the post-operative exo-
genous endophthalmitis after cataract surgery.
Diagnostic challenges
The diagnosis of intraocular TB is a difficult problem. Cultures
and PCR are often negative from intraocular fluids. Whether
these are true-negatives, false-negatives, or simply negative
because the presentation is an inflammation to bacillus
antigens as opposed to a true infectious inflammation is often
impossible to determine with any one patient. When the
inflammation involves the posterior retina, choroid, or optic
nerve, biopsy is often extremely difficult if not impossible.
Obtaining intraocular fluids to be sent for culture to confirm
the diagnosis of ocular TB is important, however it is not
always possible and is limited by the small volume and low
bacillary concentration commonly obtained.
PCR has been tested on ocular fluid since small amounts of
bacilli can be amplified. PCR is a promising technique that
may play an important role in the future of ocular TB
diagnosis, however both accuracy (high specificity but lim-
ited sensitivity) and laboratory technical issues remain
important obstacles to its widespread use, although muchhas been written about its usefulness in ocular TB.9 Further-
more, in a recent review, TB guidelines for the diagnosis of
ocular TB including the use of PCR have been proposed but
not validated in the published literature.9 Gamma-interferon
assays are in their infancy in terms of their ability to diagnose
intraocular TB.10
These issues are compounded in many countries of high TB
incidence where access to biopsy, PCR testing, gamma-inter-
feron testing, and (in some cases) culture, are largely una-
vailable. As a result the clinician is often left with a clinical
picture of ‘presumed ocular TB’, the result of the tuberculin
skin test (TST), and the chest radiograph (CXR). The TST,
although helpful, is also fraught with inaccuracy.11 The posi-
tive predictive value of the TST to diagnose active TB is low.
In fact, the TSTwill be falsely negative in 30% of patients with
active TB.12 The positive predictive value of the TST in
diagnosing active TB is further reduced in the immunocom-
promised patient. If the CXR demonstrates evidence of pre-
sent or previous TB, or there are other systemic
manifestations of active TB disease, the post-test probability
of disease increases, but these are exceptions rather than the
rule. In a case series examining patients with presumptive TB
uveitis, 17 out of 18 cases with a therapeutic response to
isoniazid did not demonstrate any evidence of active or
inactive TB on CXR.13
Ocular diagnostic testing such as fluorescein angiography,
indocyanine green angiography, ocular coherence topogra-
phy, ultrasonic biomicroscopy, and b scan ocular ultrasound
may help in selected cases. They can certainly be used to
help diagnose complications of TB uveitis, but are rarely a
primary diagnostic modality for this entity. Unfortunately, all
too often, part of the diagnostic criteria becomes the
patient’s response to anti-TB therapy: those that respond
with a significant quieting of intraocular inflammation after a
period of non-response to anti-inflammatories are presumed
to have a diagnosis of TB uveitis.11
Treatment challenges
Failure to consider TB in the differential diagnosis of intrao-
cular inflammation may have catastrophic consequences, as
the immunosuppressive agents often used to manage intrao-
cular inflammation may be sight- or life-threatening in
patients with active TB disease. We recommend that all
patients with intraocular manifestations consistent with TB
plus other clinical or radiologic findings of either active or
latent TB infection be treated presumptively for TB and
monitored for a response. The initial evaluation should
include a history to ascertain any TB risk factors, a CXR,
and a TST. In addition, evidence of other systemic diseases
that could account for the eye findings should be sought. The
differential diagnosis includes sarcoidosis, syphilis, toxoplas-
mosis, Behc¸et’s disease, systemic lupus erythematosus, and
other collagen vascular diseases.
Because of the difficulties in confirming the diagnosis, the
treatment of ocular TB is largely presumptive without the
benefit of susceptibility testing. There are no randomized
clinical trials to guide the management of ocular TB, and a
wide range of practices have been reported in the literature.
In fact, the Canadian,12 American,14 British,15 and South
African16 national TB guidelines do not contain information
regarding ocular TB diagnosis and do not offer any specific
434 G.G. Alvarez et al.recommendations on treatment. Recent case series report-
ing the use of as few as one and as many as four anti-
tuberculous drugs for treatment lengths ranging from 6 to
18 months have been described.8,17—19 The outcomes
reported in these studies are variable and cannot be directly
attributed to the treatment regimens used because of dif-
ferences in the pre-test likelihood of ocular TB, severity of
ocular disease prior to treatment, use of concomitant sys-
temic steroids, and rates of HIV co-infection with varying
degrees of immunosuppression.
When susceptibility testing is not available, we recom-
mend treating presumptive intraocular TB using the same
approach as with other forms of extrapulmonary TB. Multi-
drug therapy should be used, with four first-line drugs (iso-
niazid, rifampin, pyrazinamide, and ethambutol) for a 2-
month initiation phase. If there is no reduction in intraocular
inflammation on ophthalmologic examination after the 2-
month initiation phase, the utility of further anti-tuberculous
therapy should be reassessed as the likelihood of intraocular
TB is low. The exception is those rare cases in which intrao-
cular TB infection is demonstrated by culture, histopathol-
ogy, or PCR. If there is evidence of a clinical response to
treatment after the 2-month initiation phase, a 4-month
consolidation phase should follow using two first-line drugs
(isoniazid and rifampin). Although symptoms may not com-
pletely resolve, especially in advanced disease, a demon-
strable reduction in inflammation is expected.
Steroids
Steroids are recommended in other forms of extrapulmonary
TB, specifically, TB pericarditis20 and meningitis,21 however
no clinical trials exist on the efficacy of topical or systemic
steroids in ocular TB. In our experience, topical and some-
times even periocular injection, or systemic steroids may be
used as complementary treatment to reduce inflammation in
patients on an appropriate anti-TB regimen. Systemic ster-
oids, in addition to the anti-tuberculous treatment, are
sometimes considered for patients with persistent ocular
inflammation or retinal vasculitis, however no clinical trials
have proven their efficacy.
Treatment of drug-resistant TB
In areas with a high rate of drug resistance (isoniazid or
rifampin resistance rates greater than 10%),22 it seems pru-
dent to use three first-line drugs for the continuation phase.
Patients with suspected multidrug-resistant (MDR) or exten-
sively drug-resistant (XDR) TB should be managed on a case-
by-case basis with guidance from an expert in the manage-
ment of drug-resistant TB; however, the outcome is likely to
be poor.
HIV patients
Although the treatment duration and medications used to
treat TB patients who have HIV are the same, co-infection
poses a particularly difficult challenge. Starting antiretro-
viral therapy concomitantly may improve survival by restor-
ing the immune system,23 however it can also result in a
paradoxical flare in the patient’s ocular disease secondary toimmune reconstitution inflammatory syndrome (IRIS).18,24
Furthermore, the risk of side effects due to drug—drug
interactions is increased by starting TB and HIV treatment
concomitantly.23 TB treatment should be started immedi-
ately after the diagnosis of TB in co-infected patients, how-
ever the optimal timing for starting antiretrovirals is not
known and should be managed by an expert. In general,
antiretrovirals are started earlier in patients with severe
immunocompromise as measured by the CD4 count, and
those that are more stable can perhaps wait until after
the first 2 months of intensive phase TB treatment have been
completed to start antiretrovirals.25
In summary, TB is a treatable cause of intraocular inflam-
mation, and failure to consider this diagnosis and treat
accordingly may have catastrophic consequences. A multi-
drug regimen should be used, with close monitoring to
document clinical response. Until better diagnostic modal-
ities are available, a high index of clinical suspicion and early
presumptive treatment are crucial to achieving favorable
outcomes in patients with ocular TB.
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